Consequently, there is a pressing need for a more thorough and robust comparison of the risk of HF between insulin and alternative therapies, accounting carefully for confounding due to differences in patient populations, in order to guide T2DM management recommendations [13-18]. This evidence concerns the gene INS and hydrops fetalis.